{
  "task_id": "genome_003",
  "domain": "KEGG_BRITE",
  "autonomy_type": "ordered table",
  "oracle_output_cardinality": 8,
  "instruction": "I am compiling a table of the approval order of systemic drugs for plaque psoriasis in Japan. Process as follows: first, within the scope of systemic drugs for plaque psoriasis approved in Japan by the end of 2024, identify the active ingredients that act on the IL-17/IL-23 signaling axis; then exclude all topical drugs and systemic drugs acting on other axes. Next, sort these active ingredients by their first approval date in Japan from earliest to latest; if approved on the same day, sort by DRUG_ID in ascending order. Finally, output a multi-row table with each row formatted as <DRUG_ID>|<Name>|<ATC>|<Target_branch>|<PMDA_date>.",
  "start_url": "https://www.kegg.jp/brite/br08301",
  "output_format": "Output a multi-row table with each row formatted as <DRUG_ID>|<Name>|<ATC>|<Target_branch>|<PMDA_date>.",
  "oracle_answer": "D09967|Secukinumab|L04AC10|IL17A|2014/12/26\nD10061|Brodalumab|L04AC12|IL17RA|2016/7/4\nD10071|Ixekizumab|L04AC13|IL17A|2016/7/4\nD10438|Guselkumab|L04AC16|IL23A|2018/3/23\nD11052|Risankizumab|L04AC18|IL23A|2019/3/26\nD10400|Tildrakizumab|L04AC17|IL23A|2020/6/29\nD11550|Bimekizumab|L04AC21|IL17A/IL17F|2022/1/20\nD11817|Deucravacitinib|L04AF07|TYK2|2022/9/26",
  "metadata": {
    "State-Gated Retrieval": [
      "Retain only the active ingredients that truly act on the IL-17/IL-23 signaling axis among systemic drugs for plaque psoriasis approved in Japan by 2024-12-31.",
      "The candidate set must cover the ligand side, receptor side, and TYK2 kinase side, not just the interleukin ligand side.",
      "Sort final entries by Japan first approval date in ascending order; if on the same day, sort by DRUG_ID in ascending order."
    ],
    "dependency_type": "Data + Control",
    "intra_chain": true,
    "inter_chain": true,
    "data_dependency": [
      "KEGG disease/drug entry points yield the Japan-approved systemic plaque-psoriasis drug cohort through 2024-12-31",
      "each drug entry yields target branch, ATC, systemic-use validity, and Japan approval date for IL-17/IL-23-axis candidates",
      "final rows are produced only after ligand-side, receptor-side, and kinase-side candidates are jointly reconciled and re-sorted by Japan approval date"
    ],
    "control_dependency": [
      "entry-point coverage must include receptor-side IL17RA and kinase-side TYK2 mechanisms when downstream drug pages expose them, rather than staying ligand-only",
      "Ustekinumab must be removed only when target interpretation shows IL12 + IL23A rather than the IL-17/IL-23-axis criterion required here",
      "systemic-use, Japanese 3999, and PMDA-date filtering must be applied after each expansion of the candidate set rather than attached to the earlier ligand-only state"
    ],
    "freeze": {
      "historical_window": "Japanese plaque-psoriasis systemic drugs approved on or before 2024-12-31; current KEGG drug-entry annotations supply target branches and Japan approval dates"
    },
    "answer_type": "multi-row ordered table"
  },
  "rubric": {
    "inclusion_conditions": [
      "Retain only the active ingredients that truly act on the IL-17/IL-23 signaling axis among systemic drugs for plaque psoriasis approved in Japan by 2024-12-31.",
      "The candidate set must cover the ligand side, receptor side, and TYK2 kinase side, not just the interleukin ligand side.",
      "Sort final entries by Japan first approval date in ascending order; if on the same day, sort by DRUG_ID in ascending order."
    ],
    "exclusion_conditions": [
      "Exclude topical drugs, non-systemic drugs, or entries outside the specified historical freeze window.",
      "Exclude entries such as Ustekinumab whose actual target is IL12 + IL23A and which do not meet the IL-17/IL-23 axis criterion required here.",
      "Exclude results that miss Brodalumab or Deucravacitinib due to looking only at the ligand side."
    ],
    "normalization": {
      "field_separator": "|",
      "record_separator": "\n",
      "header_row": "omit the header row; emit data rows only",
      "schema": [
        "DRUG_ID",
        "Name",
        "ATC",
        "Target_branch",
        "PMDA_date"
      ],
      "PMDA_date": "use the canonical KEGG-style date format YYYY/M/D with no zero-padding requirement beyond the source value",
      "Target_branch": "emit the most specific target branch visible in the source path; when multiple parallel branches survive, join them with `/`",
      "sorting_or_selection": {
        "primary": "PMDA_date ascending",
        "secondary": "DRUG_ID ascending"
      }
    }
  }
}